Universal Beteiligungs und Servicegesellschaft mbH Has $3.90 Million Holdings in Prestige Consumer Healthcare Inc. $PBH

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 22.9% in the third quarter, HoldingsChannel reports. The firm owned 62,528 shares of the company’s stock after acquiring an additional 11,637 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Prestige Consumer Healthcare were worth $3,902,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PBH. AQR Capital Management LLC raised its position in shares of Prestige Consumer Healthcare by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after acquiring an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Prestige Consumer Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after buying an additional 1,289 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the period. Jane Street Group LLC lifted its holdings in Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock worth $9,010,000 after acquiring an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the period. Institutional investors own 99.95% of the company’s stock.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 719 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the transaction, the vice president directly owned 42,329 shares of the company’s stock, valued at approximately $2,539,740. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Analysts Set New Price Targets

PBH has been the topic of a number of research analyst reports. Jefferies Financial Group dropped their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Oppenheimer cut their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.33.

Prestige Consumer Healthcare Stock Down 2.5%

NYSE:PBH opened at $64.03 on Wednesday. Prestige Consumer Healthcare Inc. has a twelve month low of $57.25 and a twelve month high of $90.04. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of 15.89, a price-to-earnings-growth ratio of 2.06 and a beta of 0.40. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. The stock’s 50 day moving average price is $62.23 and its two-hundred day moving average price is $64.49.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.10. The business had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm’s revenue was down 3.4% on a year-over-year basis. During the same period last year, the business earned $1.09 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).